Abstract |
We evaluated clinical activity of ⁹⁰Yttrium-ibritumomab (⁹⁰Y- ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma--arisen at any extranodal site--received ⁹⁰Y- ibritumomab tiuxetan at the activity of 0.4 mCi/kg. Median age was 57 years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3 years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3 years, 12 of them after >5 years. ⁹⁰Y- ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients.
|
Authors | Anna Vanazzi, Chiara Grana, Cristiano Crosta, Giancarlo Pruneri, Stefania Rizzo, Davide Radice, Antonello Pinto, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli |
Journal | Hematological oncology
(Hematol Oncol)
Vol. 32
Issue 1
Pg. 10-5
(Mar 2014)
ISSN: 1099-1069 [Electronic] England |
PMID | 23696416
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 John Wiley & Sons, Ltd. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Yttrium Radioisotopes
- Rituximab
- ibritumomab tiuxetan
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Combined Modality Therapy
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Hematologic Diseases
(chemically induced)
- Humans
- Kaplan-Meier Estimate
- Lymphoma, B-Cell, Marginal Zone
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Prospective Studies
- Radioimmunotherapy
- Recurrence
- Rituximab
- Salvage Therapy
- Stomach Neoplasms
(drug therapy, radiotherapy)
- Treatment Outcome
- Yttrium Radioisotopes
(administration & dosage, adverse effects, therapeutic use)
|